PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Aggarwal, Rohit
TI  - Autoantibodies Predict Treatment Response to Rituximab in Myositis
DP  - 2012  01
TA  - MD Conference Express
PG  - 14--14
VI  - 12
IP  - 19
4099  - http://mdc.sagepub.com/content/12/19/14.1.short
4100  - http://mdc.sagepub.com/content/12/19/14.1.full
AB  - The presence of myositis-associated autoantibodies is the strongest predictor of improvement in patients with adult and juvenile myositis treated with B-cell depletion. This article describes findings from the Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis [RIM] study, in which baseline clinical, laboratory, and serologic predictors of response were examined in rituximab-treated patients with refractory myositis, defined as failure of steroids and at least 1 other immunosuppressive agent.